**Table 1.** Summary of Enrolled Studies

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author, Year | Country | Study Type | Treatment | Number of Patients | Median Age (range) | Male (%) | Outcome |
| Williams, 2016 | US | Prospective | FAM | 36 | 57 (23-72) | 53% | PFT, cGVHD, QoL, steroid taper |
| Lucid, 2010 | US | Prospective | ECP | 9 | 38 (21-54) | 44% | PFT |
| Brownback, 2015 | US | Prospective | ECP | 8 | 43.5 (27-54) | 63% | PFT, OS, steroid taper |

Abbreviations: cGVHD, chronic graft-versus-host disease; ECP, extracorporeal photopheresis; FAM, fluticasone/azithromycin/montelukast; OS, overall survival; PFT, pulmonary function tests; QoL, quality of life; US, United States.